Improving attention in individuals with Long COVID-19
Intensive Attention Training to Treat Brain Fog in Individuals With Long-Covid
This study is testing whether a virtual attention training program can help people with Long COVID improve their brain fog symptoms and cognitive function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shirley Ryan AbilityLab Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06503874 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the feasibility, acceptability, and efficacy of an attention training intervention called Attention Process Training (APT-3) for treating brain fog symptoms in individuals suffering from Long COVID. The study will assess whether this program can be effectively delivered virtually and whether it can improve cognitive function in participants. Previous evidence suggests that APT-3 is effective for individuals with acquired brain injuries, but its application for Long COVID brain fog is still under investigation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 who have a confirmed history of SARS-CoV-2 infection and are experiencing cognitive symptoms related to Long COVID.
Not a fit: Patients with pre-existing neurological conditions or severe depression may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve cognitive function and quality of life for patients experiencing brain fog due to Long COVID.
How similar studies have performed: While APT-3 has shown promise in treating attention deficits in acquired brain injuries, its efficacy for Long COVID brain fog is still being explored and is considered a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-65 years. Live in the Chicagoland area * A history of confirmed SARS-CoV-2 infection. * Subjective reports of cognitive symptoms that interfere with everyday activities, starting on or shortly after SARS-CoV-2 infection. * Continuation or development of Long-Covid brain fog 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation. * Objective attentional deficits as measured by the Conners CPT-312, and/or the Digit Span subtest (WAIS- III13). * Able to use a keyboard. * Able to understand and communicate in English. * Able to consent independently. Exclusion Criteria: * Being hospitalized due to COVID-19 diagnosis for more than 3 days. * Pre-morbid neurological conditions that could potentially affect cognition, such as Parkinson's Disease, Alzheimer's Dementia, acquired brain injury. * Severe depression. * Currently enrolled in cognitive training or physical exercise training. * Receiving chemotherapy or radiation within last 6 months. * Active substance abuse.
Where this trial is running
Chicago, Illinois
- Shirley Ryan AbilityLab — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Shira Cohen-Zimerman, PhD — Shirley Ryan AbilityLab
- Study coordinator: Kathryn Magee, MHS
- Email: LongCovid@sralab.org
- Phone: (312)238-6451
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.